Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00674141
Recruitment Status : Withdrawn (was not approved by the ministry of health)
First Posted : May 7, 2008
Last Update Posted : June 3, 2010
Information provided by:
Hadassah Medical Organization

Brief Summary:
The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients

Condition or disease Intervention/treatment Phase
MS Patient With Relpasing Remitting Attacks Drug: Dexamethasone soduim phosphate Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Nasal Administration of Dexamethasone for MS Treatment
Study Start Date : July 2008
Estimated Primary Completion Date : December 2008
Estimated Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
only one experimental treated group
Drug: Dexamethasone soduim phosphate
nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment

Primary Outcome Measures :
  1. reduction in the EDSS functional system score [ Time Frame: four months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • MS patients with esatblished relapsing remitting attacks
  • increase in EDSS of at least 1 point for a least one day

Exclusion Criteria:

  • children under 18
  • pregnant patients
  • patients with diabetes
  • known allergy to steroids
  • patients who received steroids within 3 months prior to the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00674141

Layout table for location information
Hadassah Medical Organization
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Elka Touitou, PhD, Prof. Hebrew University, Jerusalem. Israel
Layout table for additonal information
Responsible Party: Prof. Dminitrios Karussis, Hadassah Medical Organization Identifier: NCT00674141    
Other Study ID Numbers: MS089-HMO-CTIL
First Posted: May 7, 2008    Key Record Dates
Last Update Posted: June 3, 2010
Last Verified: May 2008
Keywords provided by Hadassah Medical Organization:
Multiple Sclerosis, relapsing remitting, Dexamethasone
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents